Callan Family Office LLC Invests $1.13 Million in Zoetis Inc. (NYSE:ZTS)

Callan Family Office LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,917 shares of the company’s stock, valued at approximately $1,127,000.

Several other institutional investors also recently bought and sold shares of the company. Howard Capital Management Group LLC increased its holdings in shares of Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after acquiring an additional 883 shares in the last quarter. Principal Financial Group Inc. grew its position in Zoetis by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after purchasing an additional 351,372 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its stake in Zoetis by 62.8% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 3,020 shares of the company’s stock valued at $590,000 after purchasing an additional 1,165 shares in the last quarter. Summit Global Investments raised its holdings in shares of Zoetis by 344.8% in the third quarter. Summit Global Investments now owns 5,173 shares of the company’s stock worth $1,011,000 after buying an additional 4,010 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter worth $33,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research reports. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $170.34 on Friday. The company has a market capitalization of $76.28 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company’s fifty day moving average price is $166.72 and its 200 day moving average price is $176.78. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.